Articles related to CAR T-CELL THERAPIES

Infections account for over 50% of nonrelapse deaths in CAR T-cell therapy patients, outweighing therapy-specific toxicities like ICANS and CRS.

Teclistamab, a BCMA bispecific antibody, demonstrates a promising 63% overall response rate in heavily pretreated R/R MM patients, with manageable toxicity compared to CAR T-cell therapy.

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

CARsgen Therapeutics faces a critical juncture as the FDA places a clinical hold on three of its key CAR-T cell therapy candidates, highlighting the paramount importance of manufacturing standards in the realm of advanced oncology treatments.

Discover how CRISPR-engineered CD45 CAR T-cells could alter the treatment landscape for various blood cancers, offering a more versatile and less risky approach.

The rapid exhaustion of T cells upon encountering a tumor, as revealed in a recent study, challenges existing theories and may have profound implications for cancer immunotherapies. Explore the findings to understand how this discovery could influence the future of personalized treatment.